Trial Profile
Ascending single dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of SAM-315 administered orally to healthy adult subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jan 2010
Price :
$35
*
At a glance
- Drugs SAM 315 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 25 Jul 2007 New trial record.